PTCT
PTC Therapeutics Inc

4,283
Mkt Cap
$6.07B
Volume
488,271.00
52W High
$77.46
52W Low
$35.95
PE Ratio
8.84
PTCT Fundamentals
Price
$78.39
Prev Close
$75.60
Open
$76.63
50D MA
$66.37
Beta
1.15
Avg. Volume
1.03M
EPS (Annual)
-$4.73
P/B
-38.80
Rev/Employee
$859,190.63
Loading...
Loading...
News
all
press releases
Leerink Partnrs Has Negative Outlook of PTCT FY2026 Earnings
PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Research analysts at Leerink Partnrs dropped their FY2026 EPS estimates for PTC Therapeutics in a report issued on Sunday, November 16th. Leerink...
MarketBeat·3h ago
News Placeholder
More News
News Placeholder
PTC Therapeutics to Host R&D Day
PTC Therapeutics to Host R&D Day PTC Therapeutics to Host R&D Day PR Newswire WARREN, N.J., Nov. 20, 2025 Event to take place on Dec. 2, 2025 in New York City WARREN, N.J., Nov. 20, 2025 /PRNewswire...
PR Newswire·4h ago
News Placeholder
Rockefeller Capital Management L.P. Buys 7,751 Shares of PTC Therapeutics, Inc. $PTCT
Rockefeller Capital Management L.P. lifted its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 1.7% during the 2nd quarter, according to its most recent disclosure with the SEC. The...
MarketBeat·1d ago
News Placeholder
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) have received an average rating of "Moderate Buy" from the seventeen ratings firms that are presently covering the company, MarketBeat...
MarketBeat·1d ago
News Placeholder
PTC Therapeutics (NASDAQ:PTCT) Reaches New 52-Week High - Here's Why
PTC Therapeutics (NASDAQ:PTCT) Hits New 52-Week High - Still a Buy...
MarketBeat·2d ago
News Placeholder
Savant Capital LLC Sells 5,487 Shares of PTC Therapeutics, Inc. $PTCT
Savant Capital LLC lessened its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 39.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The...
MarketBeat·2d ago
News Placeholder
9,941 Shares in PTC Therapeutics, Inc. $PTCT Acquired by Vise Technologies Inc.
Vise Technologies Inc. acquired a new stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the second quarter, according to the company in its most recent 13F filing with the...
MarketBeat·3d ago
News Placeholder
Emma Reeve Sells 7,333 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock
PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) Director Emma Reeve sold 7,333 shares of the firm's stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an...
MarketBeat·4d ago
News Placeholder
PTC Therapeutics, Inc. $PTCT Shares Sold by Candriam S.C.A.
Candriam S.C.A. cut its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 6.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange...
MarketBeat·4d ago
News Placeholder
Campbell & CO Investment Adviser LLC Acquires Shares of 14,893 PTC Therapeutics, Inc. $PTCT
Campbell & CO Investment Adviser LLC acquired a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and...
MarketBeat·4d ago

Latest PTCT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.